Comparison of cytogenetic damage in groups of patients with myeloproliferative neoplasms, depending on the presence or absence of V617F mutation in JAK2 gene

S. N Kolubaeva; Колюбаева С. Н; A. S Polyakov; Поляков А. С; A. V Kissel; Киссель А. В; L. A Myakoshina; Мякошина Л. А; N. A Viktorova; Викторова Н. А; S. S Ushanov; Ушанов С. С; A. A Titova; Титова А. А; A. M Ivanov; Иванов А. М; Ya. A Noskov; Носков Я. А; S. G Bologov; Бологов С. Г; S. V Voronin; Воронин С. В

doi:10.23868/gc120616

Comparison of cytogenetic damage in groups of patients with myeloproliferative neoplasms, depending on the presence or absence of V617F mutation in JAK2 gene

Authors: Kolubaeva S.N¹, Polyakov A.S¹, Kissel A.V¹, Myakoshina L.A¹, Viktorova N.A¹, Ushanov S.S¹, Titova A.A¹, Ivanov A.M¹, Noskov Y.A¹, Bologov S.G¹, Voronin S.V¹
Affiliations:
1. S.M. Kirov Military Medical Academy
Issue: Vol 11, No 3 (2016)
Pages: 150-152
Section: Articles
URL: https://genescells.ru/2313-1829/article/view/120616
DOI: https://doi.org/10.23868/gc120616
ID: 120616

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Myeloproliferative neoplasms are diseases characterized by clonal proliferation of myeloid bone marrow. At present, it describes a number of genetic markers myeloproliferative neoplasms, such as JAK2v617f. However the nature of violations in the progenitor cells is still not clear. In this study, a comparative analysis of cytogenetic damage in patients with myeloproliferative neoplasms with a mutation JAK2v617f and without this damage. The study showed that differences in the number and diversity of received clonal damage in both groups was not significant. Given the small number of patients with clonal cells, it can be assumed that cytogenetic analysis diagnostically significant.

Keywords

JAK2v617f, myeloproliferative neoplasm, polycythemia vera, essential thrombocytosis, myelofibrosis, JAK2v617f, cytogenetic analysis

Full Text

References

Tefferi A., Vardiman J.W. Classification and of myeloproliferative neoplasms: Tye 2008 World Health Organization criteria and point of care diagnostic algotryms. Leukemia 2008; 22: 14-22.
Heim S., Mitelman F. Chronic myeloproliferative neoplasms. In: Cancer Cytogenetics, third edition. Canada: Wiley-Blackwell; 2009; p. 209-32.
Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Damesh ek's 54 year old speculation comes of age. Best Pract. Res. Clin. Haematol. 2007; 20: 5-12.
Scott L.M., Tong W., Levine R.L. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007; 356: 459-68.
Nussenzveig R.H., Swierczek S.I., Jelinek J. et al. Polycythemia vera is not initiated by JAK V617F mutation. Exp. Hematol. 2007; 35: 32-8.
Theocharides A., Boissinot M., Girodon F. et al. Leukemic blasts in transformed JAK2V617F-positive myeloproliferative disorders are frequently negative for the JAK2V617F mutation. Blood 2007; 110: 375-79.
Pietra D., Li S., Brisci A. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2007; 111: 1686-89.
Eds. L. Shaffer, N. Tommerup. An international system for human cytogenetic nomenclature. In: Recommendations of International Standing Commitee on Human Cytogenetic Nomenclature. Basel: S. Karger; 2013.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Comparison of cytogenetic damage in groups of patients with myeloproliferative neoplasms, depending on the presence or absence of V617F mutation in JAK2 gene

Full Text

Abstract

Keywords

Full Text

About the authors

References

Supplementary files

This website uses cookies